RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving revenues of RMB 742 million (USD 103.9 million), marking a significant 75.59% increase year-on-year. This growth was primarily fueled by heightened sales of its flagship products, telitacicept and disitamab vedotin.
The company’s research and development expenditures reached RMB 806 million, reflecting a 49.18% year-on-year rise, while sales expenses totaled RMB 390 million, an 11.28% increase driven by the expanding network of access hospitals and pharmacies for these products.
Telitacicept, a novel recombinant fusion protein targeting both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), received conditional approval in China for systemic lupus erythematosus (SLE) in March 2021, transitioning to full approval in November 2023. Disitamab vedotin, China’s first domestically developed antibody-drug conjugate (ADC), gained conditional market approval in June 2021 as a third-line treatment for HER2-positive gastric cancer (GC), with a subsequent approval for treating urothelial cancer (UC) granted by the NMPA on December 31, 2021.- Flcube.com
